Showing results (161-170 of 302) with videos related to

Sort By:
Pageof 31
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Blood Advances|August 22, 2020
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphomaPaolo Strati, Loretta J Nastoupil, Jason Westin, et al.
Haematologica|May 2, 2016
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesNathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
Ejhaem|February 2, 2026
Venous Thromboembolism in Aggressive B-Cell Lymphoma Patients Treated with CD19 CAR-T Therapy: Single-Institution StudyNeha Venkatesh, Kevin Milligan, Julia Parrish, et al.
British Journal of Haematology|December 12, 2024
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)Paolo Strati, Richy Agajanian, Izidore S Lossos, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2024
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular LymphomaPaola Ghione, M Lia Palomba, Markqayne D Ray, et al.
International Journal of Cancer|April 29, 2014
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphomaKui Shin Voo, Myriam Foglietta, Elena Percivalle, et al.
The Journal of Clinical Investigation|June 19, 2025
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphomaSoumya Poddar, Jiali Yan, Gayatri Tiwari, et al.
Leukemia Research|August 13, 2022
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insightsNaveen Pemmaraju, Nathaniel R Wilson, Jayastu Senapati, et al.
Pageof 31